Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050271 | 1.00 | ADORA3 (0.56) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL21050279 | 0.90 | ADORA3 (0.56) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL21050300 | 0.90 | ADORA3 (0.56) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL21050299 | 0.84 | ADORA3 (0.50) | ADORA3HPRT1PNP | |
| SCHEMBL6315056 | 0.84 | ADORA3 (0.59) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL9242370 | 0.84 | ADORA3 (0.59) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL9764502 | 0.84 | ADORA3 (0.59) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL21100357 | 0.83 | ADORA3 (0.58) | ADORA3HPRT1PNPTK1 | |
| SCHEMBL21050250 | 0.82 | AHCY (0.39) | ADORA3PNP | |
| SCHEMBL21050287 | 0.82 | AHCY (0.39) | ADORA3PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | claimed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | claimed |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | ADORA3 712/4885HPRT1 5/4885PNP 20/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | ADORA3 712/4885HPRT1 5/4885PNP 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.